Background: Components of the insulin-like growth factor (IGF) system have been associated with several cancers, but very few studies are available for ovarian cancer. Methods: A case-control study conducted between 1999 and 2003 in Italy, including a total of 59 women with incident, histologically confirmed ovarian cancer and 108 controls admitted to the same hospital network as cases, for acute non-neoplastic diseases. All subjects were interviewed using a validated questionnaire. Results: After adjustment for potential confounders, the multivariate odds ratios for the highest versus the lowest tertile of various IGF components were 0.6 (95% confidence interval, CI: 0.2–1.4) for free IGF-I, 0.4 (CI: 0.1–1.5) for total IGF-I, 2.6 (CI: 0.9–6.9) for IGF-binding protein (IGFBP)-1, and 0.2 (CI: 0.0–0.6) for IGFBP-3. Conclusions: This study suggests a protective role of IGFBP-3 and a positive association of IGFBP-1 with ovarian cancer. The complex role of the IGF system in ovarian carcinogenesis deserves further clarification.

Keywords:
Ovarian cancer, IGF-I, IGFBP-1, IGFBP-3, Case-control study
1.
Riman T, Persson I, Nilsson S: Hormonal aspects of epithelial ovarian cancer: Review of epidemiological evidence. Clin Endocrinol (Oxf) 1998;49:695–707.
2.
La Vecchia C: Epidemiology of ovarian cancer: A summary review. Eur J Cancer Prev 2001;10:125–129.
3.
Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, Conti E, Montella M, La Vecchia C: Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001;12:337–341.
4.
Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774–1786.
5.
Karasik A, Menczer J, Pariente C, Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab 1994;78:271–276.
6.
Beck EP, Russo P, Gliozzo B, Jaeger W, Papa V, Wildt L, Pezzino V, Lang N: Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue. Gynecol Oncol 1994;53:196–201.
7.
Hofmann J, Wegmann B, Hackenberg R, Kunzmann R, Shulz KD, Haveman K: Production of insulin-like growth factor binding proteins by human ovarian carcinoma cells. J Cancer Res Clin Oncol 1994;120:137–142.
8.
Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS: Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 1997;82:2308–2313.
9.
Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R: Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002;101:549–554.
10.
Lukanova A, Lundin E, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Riboli E, Hallmans G, Berrino F, Zeleniuch-Jacquotte A, Toniolo P, Kaaks R: Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control 2003;14:285–292.
11.
Franceschi S, Barbone F, Negri E, Decarli A, Ferraroni M, Filiberti R, Giacosa A, Gnagnarella P, Nanni O, Salvini S: Reproducibility of an Italian food frequency questionnaire for cancer studies. Results for specific nutrients. Ann Epidemiol 1995;5:69–75.
12.
Thierry van Dessel HJHM, Chandrasekher Y, Yap OWS, Lee PDK, Hintz RL, Faessen GHJ, Braat DDM, Fauser BCJM, Giudice LC: Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. J Clin Endocrinol 1996;81:1224–1231.
13.
LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127–137.
14.
Yee D, Lee AV: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:107–115.
15.
Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, Maggi A, DiAugustine RP, Korach KS: Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem 2002;277:8531–8537.
16.
Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–89.
17.
Plymate SR, Hoop RC, Jones RE, Matej LA: Regulation of sex hormone-binding globulin production by growth factors. Metabolism 1990;39:967–970.
18.
Katsaros D, Yu H, Levesque MA, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi MJ, Diamandi A, Gordini G, Diamandis EP, Massobrio M: IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur J Cancer 2001;37:478–485.
19.
Juul A, Scheike T, Pedersen AT, Main KM, Andersson AM, Pedersen LM, Skakkebaek NE: Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Hum Reprod 1997;12:2123–2128.
20.
Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR: Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994;42:145–151.
21.
Lee PD, Giudice LC, Conover CA, Powell DR: Insulin-like growth factor binding protein-1:Recent findings and new directions. Proc Soc Exp Biol Med 1997;216:319–357.
22.
Elgin RG, Busby WH Jr, Clemmons DR: An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 1987;84:3254–3258.
23.
Busby WH, Hossenlopp P, Binoux M, Clemmons DR: Purified preparations of the amniotic fluid-derived insulin-like growth factor-binding protein contain multimeric forms that are biologically active. Endocrinology 1989;125:773–777.
24.
Signorello LB, Brismar K, Bergstrom R, Andersson S-O, Wolk A, Trichopoulos D, Adami HO: Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst 1999;91:1965–1967.
25.
Augustin LSA, Dal Maso L, Franceschi S, Talamini R, Kendall CWC, Jenkins DJA, Vidgen E, Martini P, La Vecchia C: Association between components of the insulin-like growth factor (IGF) system and endometrial cancer risk. Oncology 2004;67:54–59.
26.
McKeown-Eyssen G: Epidemiology of colorectal cancer revisited: Are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3:687–695.
27.
Giovannucci E: Insulin and colon cancer. Cancer Causes Control 1995;6:164–179.
28.
Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, et al: Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986;5:2503–2512.
29.
Kaaks R, Lukanova A: Energy balance and cancer: The role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91–106.
30.
Tran TT, Medline A, Bruce RW: Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996;5:1013–1015.
31.
Augustin LS, Franceschi S, Jenkins DJ, Kendall CW, La Vecchia C: Glycemic index in chronic disease: A review. Eur J Clin Nutr 2002;56:1049–1071.
32.
Holmes MD, Pollak MN, Hankinson SE: Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:862–867.
33.
Holmes MD, Pollak MN, Willett WC, Hankinson SE: Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:852–861.
34.
Giovannucci E, Pollack M, Liu Y, Platz EA, Mjeed N, Rimm EB, Willett WC: Nutritional predictors of insulin-like growth factor I and their relationship to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84–89.
35.
Bidoli E, La Vecchia C, Montella M, Dal Maso L, Conti E, Negri E, Scarabelli C, Carbone A, Decarli A, Franceschi S: Nutrient intake and ovarian cancer: An Italian case-control study. Cancer Causes Control 2002;13:255–261.
36.
Augustin LS, Polesel J, Bosetti C, Kendall CW, La Vecchia C, Parpinel M, Conti E, Montella M, Franceschi S, Jenkins DJ, Dal Maso L: Dietary glycemic index, glycemic load and ovarian cancer risk: A case-control study in Italy. Ann Oncol 2003;14:78–84.
37.
Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ: Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2002;11:822–828.
38.
Dal Maso L, Franceschi S, Negri E, Conti E, Montella M, Vaccarella S, Canzonieri V, Parazzini F, La Vecchia C: Body size indices at different ages and epithelial ovarian cancer risk. Eur J Cancer 2002;38:1769–1774.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.